

03/06/02
J-1059Please type a plus sign (+) inside this box

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

03-07-02

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR
1.53 (b))

Attorney Docket No. LEX-0314-USA

First Inventor Wilganowski

Title Novel Human Transporter Proteins and Polynucleotides Encoding
the Same

Express Mail Label No. EV 088047915 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application

1. Fee Transmittal Form (e.g., PTO/SB/17)
2. Applicant claims small entity status.
See 37 CFR 1.27.
3. Specification *[Total Pages* 36 *]*
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the disclosure
4. Drawing(s) (35 U.S.C. 113) *[Total Sheets* *]*
5. Oath or Declaration *[Total Pages* 2 *]*
 - a. Unexecuted (original or copy)
 - b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 - i. DELETION OF INVENTOR(S)
signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b).
6. Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. Computer Readable Form (CRF) - DISKETTE
 - b. Specification Sequence Listing on:
 - i. CD-ROM or CD-R (2 copies); or
 - ii. paper (5 pages)
- c. Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(b) Statement *(when there is an assignee)* Power of Attorney
11. English Translation Document (if applicable)
12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. Nonpublication Request under 35 U.S.C. 122
(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent
17. Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Prior application information: Examiner _____

Group Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

(Insert Customer No. or Attach bar code label here)

 Customer Number or Bar Code Labelor Correspondence address below

Name	24231		
PATENT TRADEMARK OFFICE			
Address			
City	State	Zip	
Country	Telephon		Fax

Name (Print/Type)	Lance K. Ishimoto	Registration No. (Attorney/Agent)	41,866
Signature	Lance K. Ishimoto by David W. Becker DAVID W. BECKER REG. NO. 4,071		Date
			March 6, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT **(\$)** 740.00

Complete If Known

Application Number	Not Yet Assigned
Filing Date	March 6, 2002
First Named Inventor	Wilganowski et al.
Examiner Name	Not Yet Assigned
Group Art Unit	Not Yet Assigned

Attorney Docket No. **LEX-0314-USA**

METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)										
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card	<input type="checkbox"/> Money Order	<input type="checkbox"/> Other	<input type="checkbox"/> None								
<input checked="" type="checkbox"/> Deposit Account Deposit Account Number 50-0892 Deposit Account Name _____												
The Commissioner is authorized to: (check all that apply) <input type="checkbox"/> Charge fee(s) indicated below <input type="checkbox"/> Credit any overpayments <input type="checkbox"/> Charge any additional fee(s) during the pendency of this application <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.						3. ADDITIONAL FEES Large Entity Small Entity						
						Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description		Fee Paid
						105	130	205	65	Surcharge - late filing fee or oath		
						127	50	227	25	Surcharge - late provisional filing fee or cover sheet		
						139	130	139	130	Non-English specification		
						147	2,520	147	2,520	For filing a request for ex parte		
						112	920*	112	920*	Requesting publication of SIR prior to Examiner action		
						113	1,840*	113	1,840**	Requesting publication of SIR after Examiner action		
						115	110	215	55	Extension for reply within first month		
						116	400	216	200	Extension for reply within second month		
						117	920	217	460	Extension for reply within third month		
						118	1,440	218	720	Extension for reply within fourth month		
						128	1,960	228	980	Extension for reply within fifth month		
						119	320	219	160	Notice of Appeal		
						120	320	220	160	Filing a brief in support of an appeal		
						121	280	221	140	Request for oral hearing		
						138	1,510	138	1,510	Petition to institute a public use proceeding		
						140	110	240	55	Petition to revive - unavoidable		
						141	1,280	241	640	Petition to revive - unintentional		
						142	1,280	242	640	Utility issue fee (or reissue)		
						143	460	243	230	Design issue fee		
						144	620	244	310	Plant issue fee		
						122	130	122	130	Petitions to the Commissioner		
						123	50	123	50	Processing fee under 37 CFR 1.17(q)		
						126	180	126	180	Submission of Information Disclosure Stmt		
						581	40	581	40	Recording each patent assignment per property (times number of properties)		
						146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))		
						149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))		
						179	740	279	370	Request for Continued Examination (RCE)		
						169	900	169	900	Request for expedited examination of a design application		
						Other fee (specify) _____						
						*Reduced by Basic Filing Fee Paid				SUBTOTAL (3) (\$)		

SUBMITTED BY			Complete (if applicable)		
Name (Print/Type)	Lance K. Ishimoto	Registration No. (Attorney/Agent)	41,866	Telephone	(281) 863-3333
Signature	<i>Lance K. Ishimoto by David W. Hebler DAVID W. HEBLER REG. NO. 41,866</i>			Date	March 6, 2002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization of PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Wilganowski et al.

U.S. Ser. No.: To be assigned Attorney Docket No.: LEX-0314-USA

Filing Date: March 6, 2002

For: Novel Human Transporter Proteins
and Polynucleotides Encoding the
Same

VERIFIED STATEMENT

Box Patent Application
Commission for Patents
Washington, D.C. 20231

Sir:

I, DRENDA D. THOMAS, do declare and state as follows:

1. I prepared a Sequence Listing in paper and computer readable form under 37 C.F.R. Sec. 1.821-1.825 in connection with the above-captioned patent application, both of which are being submitted herewith.
2. I hereby state that the contents of the paper and computer readable copies of the Sequence Listing are the same.

Signed,



Drenda D. Thomas

March 6, 2002

Date